Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

Small study supports the potential for QLT's drug elution technology to

reduce and sustain intraocular pressure

VANCOUVER, May 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today results from a proof of concept trial conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc., of its punctal plug drug delivery technology. The results demonstrated that QLT's drug elution technology was effective in controlling intraocular pressure (IOP) and was well tolerated.

The proof of concept, open label study was initiated to determine if a sustained administration of latanoprost using the Company's punctal plug drug delivery technology could lead to a reduction in IOP over 90 days when administered using a conventional plug design. Five patients (10 eyes) with glaucoma or ocular hypertension were enrolled at a single center. The primary efficacy endpoint was measurement of IOP. At baseline, the mean IOP was 23mmHg for the 10 eyes treated. At 90 day follow-up, the mean IOP was reduced to 17mmHg for the six eyes that remained. Data from two patients were excluded due to loss of plugs. No significant adverse events were reported.

"We are very pleased to report positive results from this preliminary proof of concept trial", said Bob Butchofsky, President and Chief Executive Officer of QLT. "Although the number of patients is small, we are encouraged by the clinically meaningful reduction in IOP that was observed and sustained for approximately 90 days. We look forward to providing you with additional details from this study at our Annual General Meeting on Wednesday, May 14."

The objective of QLT's punctal plug program is to demonstrate that the Company's drug elution technology leads to a statistically significant reduction in IOP for 90 days and that its proprietary punctal plug design can be retained comfortably in a high percentage of patients during that time period. The results presented t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Patent Offering, The patent’s technology ... or therapeutic imaging within a body lumen (open space). ... having a low cost, single-use disposable illumination and camera ... October 18, 2013 and the patent approval was received ... physician to customize the lighting and magnification of the ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has ... Market Outlook 2020 " report to their offering. ... regenerative medicine is expected to have huge marketing potential. ... in the growth of deregulated organs. Several therapeutic molecules ... to form new tissue or sometimes organ transplant is ...
(Date:5/20/2015)... NEW YORK , May 20, 2015 /PRNewswire-USNewswire/ ... announced a leadership gift of $100 million from ... help create a new laboratory building that will ... campus extension. The Marie-Josée and Henry R. Kravis ... over the FDR Drive, spanning approximately three city ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4
... Inc., announced today that the organization has not ... 2010, Paul McDaniel became the interim President and ... operations are continuing and several employees who had ... Lisa P. Sumner, Esq., Poyner Spruill LLPAttorney for ...
... LifeVantage Corporation (OTC Bulletin Board: ... science-based therapy for oxidative stress, announced today that a ... scientific journal PLoS ONE.  The study, conducted by researchers ... underlie the ability of Protandim® to suppress tumors in ...
... Science, the innovative biological products and research services business ... announced the global release of a pioneering range of ... Sigma,s proprietary CompoZr zinc finger nuclease (ZFN) ... to offer innovative tools for drug discovery, compound screening ...
Cached Biology Technology:Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study 2Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study 3Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study 4Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study 5Sigma® Life Science Enters Genetically Modified Cell Market 2Sigma® Life Science Enters Genetically Modified Cell Market 3Sigma® Life Science Enters Genetically Modified Cell Market 4
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
(Date:5/6/2015)... May 6, 2015 LifeBEAM, a developer of ... producer, announced today that they will expand their partnership ... first bio-sensing cycling helmet and the first joint project ... new colors in order to give cyclists more style ... addition, LifeBEAM and Lazer announced their plan to release ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... helped boost green foliage across the world,s arid regions ... CO2 fertilisation, according to CSIRO research., In findings based ... National University (ANU), found that this CO2 fertilisation correlated ... from 1982-2010 across parts of the arid areas studied ...
... one of the major reasons why couples travel abroad ... regulations at home or raise concerns about financial inducement, ... Yet little is known about the women who provide ... their motivation and their compensation. A study performed ...
... study performed in Belgium has shown that low-cost ... feasible and effective, with delivery rates not much ... This proof-of-principle study, say the investigators, suggests that ... that the IVF methodology can be significantly simplified ...
Cached Biology News:Deserts 'greening' from rising CO2 2Egg donation in European clinics: Why do women do it? 2Egg donation in European clinics: Why do women do it? 3IVF for 200 euro per cycle 2IVF for 200 euro per cycle 3
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
... Plus is formulated for covering tissue sections and ... soluble OR alcohol insoluble end products. ... as Fast Red or AEC that require an ... such as DAB. No heating is required prior ...
Biology Products: